Direkt zum Inhalt
Merck

N6037

Sigma-Aldrich

Neridronate

≥97% (NMR), solid, bone resorption inhibitor

Synonym(e):

6-Amino-1-hydroxyhexylidene bisphosphonic acid, Neridronic acid, Nerixia

Anmeldenzur Ansicht organisationsspezifischer und vertraglich vereinbarter Preise


About This Item

Empirische Formel (Hill-System):
C6H17NO7P2
CAS-Nummer:
Molekulargewicht:
277.15
MDL-Nummer:
UNSPSC-Code:
51111800
PubChem Substanz-ID:
NACRES:
NA.77

product name

Neridronate, ≥97% (NMR), solid

Beschreibung

may contain <1% (w/w) inorganic salts

Qualitätsniveau

Assay

≥97% (NMR)

Form

solid

Farbe

white

Löslichkeit

H2O: >5 mg/mL

Lagertemp.

2-8°C

SMILES String

NCCCCCC(O)(P(O)(O)=O)P(O)(O)=O

InChI

1S/C6H17NO7P2/c7-5-3-1-2-4-6(8,15(9,10)11)16(12,13)14/h8H,1-5,7H2,(H2,9,10,11)(H2,12,13,14)

InChIKey

PUUSSSIBPPTKTP-UHFFFAOYSA-N

Biochem./physiol. Wirkung

Neridronate is a bone resorption inhibitor. It is used to treat Osteogenesis Imperfecta, an "orphan disease" characterized by a fragility of the bone enough to be named the "illness of bones of crystal".

Piktogramme

Exclamation mark

Signalwort

Warning

H-Sätze

Gefahreneinstufungen

Acute Tox. 4 Oral

Lagerklassenschlüssel

11 - Combustible Solids

WGK

WGK 3

Flammpunkt (°F)

Not applicable

Flammpunkt (°C)

Not applicable

Persönliche Schutzausrüstung

dust mask type N95 (US), Eyeshields, Gloves


Analysenzertifikate (COA)

Suchen Sie nach Analysenzertifikate (COA), indem Sie die Lot-/Chargennummer des Produkts eingeben. Lot- und Chargennummern sind auf dem Produktetikett hinter den Wörtern ‘Lot’ oder ‘Batch’ (Lot oder Charge) zu finden.

Besitzen Sie dieses Produkt bereits?

In der Dokumentenbibliothek finden Sie die Dokumentation zu den Produkten, die Sie kürzlich erworben haben.

Die Dokumentenbibliothek aufrufen

Kunden haben sich ebenfalls angesehen

Pietro Persiani et al.
Medicine, 96(20), e6766-e6766 (2017-05-18)
The purpose of this study is to compare the results of 2 techniques, tension band wiring (TBW) and fixation with screws, in olecranon fractures in children affected with osteogenesis imperfecta (OI) type I. Between 2010 and 2014, 21 olecranon fractures
Yasmina Hamdous et al.
Journal of nanobiotechnology, 15(1), 74-74 (2017-10-19)
Biologics magnetics nanoparticles, magnetosomes, attract attention because of their magnetic characteristics and potential applications. The aim of the present study was to develop and characterize novel magnetosomes, which were extracted from magnetotactic bacteria, purified to produce apyrogen magnetosome minerals, and
M Benucci et al.
Clinical and experimental rheumatology, 27(4), 567-573 (2009-09-24)
To assess the effects of intramuscular (im) neridronate (NE) on lumbar and femoral neck BMD and on markers of bone turnover in rheumatic patients under chronic low-dose glucocorticoids (GC) therapy. Sixty-nine osteopoenic and osteoporotic patients, affected by rheumatic diseases and
Silvano Adami et al.
Calcified tissue international, 83(5), 301-307 (2008-10-24)
Compliance to osteoporosis treatment with oral bisphosphonates is very poor. Intermittent intravenous bisphosphonate is a useful alternative, but this route is not readily available. Neridronate, a nitrogen-containing bisphosphonate that can be given intramuscularly (IM), was tested in a phase 2
Luigi Gennari et al.
Mini reviews in medicinal chemistry, 9(9), 1052-1063 (2009-08-20)
Paget's disease of bone is a focal skeletal disorder characterized by the formation of structurally abnormal bone, deformity and other complications leading to significant disability and bone pain. Recently, the availability of newer, more potent nitrogen-containing bisphosphonates has improved treatment

Unser Team von Wissenschaftlern verfügt über Erfahrung in allen Forschungsbereichen einschließlich Life Science, Materialwissenschaften, chemischer Synthese, Chromatographie, Analytik und vielen mehr..

Setzen Sie sich mit dem technischen Dienst in Verbindung.